Emideltide—better known as delta sleep-inducing peptide or DSIP—was the only one of seven peptides not recommended by PCAC in July 2026. Here is what the evidence and vote mean.

Semax is a synthetic ACTH-derived heptapeptide studied primarily in Russian neurological research. It is not FDA approved. Here is what is known about its proposed uses and PCAC’s 2026 recommendation.

Epitalon—also spelled Epithalon—is promoted as a sleep and longevity peptide. Laboratory and animal findings are intriguing, but claims of proven human anti-aging effects are not supported by robust trials.

MOTS-c is a mitochondrial-derived peptide studied for metabolic signaling, exercise adaptation and aging. Most intervention data remain preclinical. Here is the science and current FDA status.

TB-500 is often marketed as thymosin beta-4, but FDA evaluated a specific seven-amino-acid fragment. Learn what research exists, where claims outrun evidence, and what PCAC’s favorable vote means.

KPV is a three-amino-acid melanocortin fragment studied for anti-inflammatory and wound-related effects. Most evidence remains preclinical; here is what PCAC’s 2026 recommendation does and does not mean.

BPC-157 is widely promoted for injury recovery and gastrointestinal health, but most published evidence is preclinical. Here is what the research, FDA review and July 2026 PCAC recommendation actually mean.

The FDA’s advisory committee recommended six peptides for possible inclusion on the 503A Bulks List—but that did not make them FDA approved or immediately legal to compound. Here is the complete guide on how we got here and what happens next.